While beta-blockers may blunt hypoglycemic responses in MASLD patients with T2DM, angiotensin receptor blockers (ARBs) and ACE inhibitors (ACEIs) show promise due to their anti-inflammatory and antifibrotic properties, as the RAAS pathway is involved in both MASLD and CVD. This evidence concerns the gene ACE and type 2 diabetes mellitus.